Literature DB >> 26039206

Who is the best alternative allotransplant donor?

R P Gale1, M Eapen2.   

Abstract

Assuming that most physicians will chose an HLA-identical sibling as the best allotransplant donor, the question arises who is the best alternative donor when an HLA-identical sibling is unavailable? The most commonly used alternative donors are HLA-identical or -mismatched unrelated donors, HLA-matched or -mismatched umbilical cord blood donor or a related, HLA-haplotype-matched related donors. Each alternative donor option has advantages and disadvantages. We discuss selected aspects of these issues based on data from randomized clinical trials and observational databases. However, because there are limited data to address specific clinical settings, quantification of expert opinion is sometimes needed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26039206      PMCID: PMC4520408          DOI: 10.1038/bmt.2015.94

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

Authors:  Vikas Gupta; Martin S Tallman; Wensheng He; Brent R Logan; Edward Copelan; Robert Peter Gale; Hanna J Khoury; Thomas Klumpp; John Koreth; Hillard M Lazarus; David I Marks; Rodrigo Martino; David A Rizzieri; Jacob M Rowe; Mitchell Sabloff; Edmund K Waller; John F DiPersio; Donald W Bunjes; Daniel J Weisdorf
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?

Authors:  R P Gale; M Eapen; B Logan; M-J Zhang; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2009-02-02       Impact factor: 5.483

3.  What does MRD in leukemia really mean?

Authors:  J M Goldman; R P Gale
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

4.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Authors:  Claudio G Brunstein; Ephraim J Fuchs; Shelly L Carter; Chatchada Karanes; Luciano J Costa; Juan Wu; Steven M Devine; John R Wingard; Omar S Aljitawi; Corey S Cutler; Madan H Jagasia; Karen K Ballen; Mary Eapen; Paul V O'Donnell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

5.  Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Authors:  Dimitri A Breems; Wim L J Van Putten; Peter C Huijgens; Gert J Ossenkoppele; Gregor E G Verhoef; Leo F Verdonck; Edo Vellenga; Georgine E De Greef; Emanuel Jacky; Johannes Van der Lelie; Marc A Boogaerts; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2005-01-04       Impact factor: 44.544

6.  Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

Authors:  Daniel Weisdorf; Mary Eapen; Annalisa Ruggeri; Mei-Jie Zhang; Xiaobo Zhong; Claudio Brunstein; Celalettin Ustun; Vanderson Rocha; Eliane Gluckman
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-26       Impact factor: 5.742

7.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

8.  Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Authors:  S M Luger; O Ringdén; M-J Zhang; W S Pérez; M R Bishop; M Bornhauser; C N Bredeson; M S Cairo; E A Copelan; R P Gale; S A Giralt; Z Gulbas; V Gupta; G A Hale; H M Lazarus; V A Lewis; M C Lill; P L McCarthy; D J Weisdorf; M A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

  8 in total
  4 in total

1.  A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.

Authors:  Jiro Inagaki; Reiji Fukano; Maiko Noguchi; Jun Okamura
Journal:  Int J Hematol       Date:  2017-02-15       Impact factor: 2.490

2.  India's First Child using PGT-M, PGT-A and HLA Matching for Helping a Sibling having β-Thalassemia Major.

Authors:  Jwal M Banker; Parul Arora; Rajni Khajuria; Manish Banker
Journal:  J Hum Reprod Sci       Date:  2019-12-17

3.  Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes.

Authors:  Zheng-Yang Song; Han-Yun Ren; Yu-Jun Dong; Yuan Li; Yue Yin; Yu-Hua Sun; Qian Wang; Wei-Lin Xu; Wei Liu; Jin-Ping Ou; Ze-Yin Liang
Journal:  Cancer Manag Res       Date:  2020-11-30       Impact factor: 3.989

Review 4.  KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection.

Authors:  Adèle Dhuyser; Alice Aarnink; Michaël Pérès; Jyothi Jayaraman; Neda Nemat-Gorgani; Marie Thérèse Rubio; John Trowsdale; James Traherne
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.